TREMFYA (Janssen-Cilag Pty Ltd)
Product name
TREMFYA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
194 (255 working days)
Active ingredients
guselkumab
Registration type
EOI
Indication
Plaque Psoriasis
TREMFYA is indicated for the treatment of paediatric patients (6 years of age or older) with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.